Biomarkers of Type 2 Airway Inflammation as Predictors of Loss of Asthma Control During Step-Down Therapy for Well-Controlled Disease: The Long-Acting Beta-Agonist Step-Down Study (LASST)

Biomarkers that can predict loss of asthma control among patients being considered for step-down therapy in well-controlled disease are lacking. To evaluate whether baseline biomarkers of type 2 airway inflammation and/or serial measurement of fractional exhaled nitric oxide (Feno) predict loss of a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The journal of allergy and clinical immunology in practice (Cambridge, MA) MA), 2020-11, Vol.8 (10), p.3474-3481
Hauptverfasser:	Bose, Sonali, Bime, Christian, Henderson, Robert J., Blake, Kathryn V., Castro, Mario, DiMango, Emily, Hanania, Nicola A., Holbrook, Janet T., Irvin, Charles G., Kraft, Monica, Peters, Stephen P., Reibman, Joan, Sugar, Elizabeth A., Sumino, Kaharu, Wise, Robert A., Rogers, Linda
Format:	Artikel
Sprache:	eng
Schlagworte:	Agonists Allergies Asthma Asthma - diagnosis Asthma - drug therapy Atopy Biomarkers Blood Breath Tests Bronchodilators Corticosteroids Diaries Eosinophil peroxidase Exhalation Fractional exhaled nitric oxide Humans IgE Immunoglobulin E Inflammation Leukocytes (eosinophilic) Nitric Oxide Patients Peroxidase Respiratory tract Respiratory tract diseases Spirometry Step-down therapy Variables
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!